Pharmacogenetic impact on the methylphenidate-hydrocloride treatment in children with attention-deficit hyperactivity disorder
10.11852/zgetbjzz2023-0489
- VernacularTitle:药物遗传学对注意缺陷多动障碍儿童盐酸哌甲酯治疗的影响
- Author:
Miaomiao REN
1
;
Li CHEN
1
Author Information
1. Child Healthcare Department (Health Management Department), Children′s Hospital of Chongqing Medical University; National Clinical Research Center for Child Health and Disorders; Ministry of Education Key Laboratory of Child Development and Disorders; China International Science and Technology Cooperation Base of Child Development and Critical Disorders; Chongqing Key Laboratory of Child Nutrition and Health, Chongqing 400014
- Publication Type:Journal Article
- Keywords:
attention-deficit hyperactivity disorder;
pharmacogenetics;
methylphenidate-hydrocloride;
pharmacokinetics;
pharmacodynamics
- From:
Chinese Journal of Child Health Care
2024;32(3):296-300
- CountryChina
- Language:Chinese
-
Abstract:
Attention-deficit hyperactivity disorder (ADHD) is one of the most common chronic neurodevelopmental disorders in childhood.It is mainly manifested as inattention, hyperactivity, and impulsivity that are inconsistent with the development level, which may lead to multiple functional impairments and place heavy burdens on individuals, families, and society.Methylphenidate hydrochloride (MPH) is a first-line treatment drug for ADHD, which is widely used in clinical practice.However, some patients have no response to drug treatment and adverse reactions often cause premature termination of treatment.Introducing the concept of pharmacogenetics into MPH treatment may open new avenues for individualized interventions of ADHD.This paper aims to review the impact of pharmacogenetics on MPH treatment in children with ADHD and to provide references for clinical drug treatment and management.
